Hepatitis C virus (HCV) RNA loads are measured sporadically in HCV-positive individuals. However, the prognostic value of these isolated measurements for predicting progression to acquired immune deficiency syndrome (AIDS) and all-cause mortality in coinfected individuals remains unclear. In this study, the prognostic value of a single HCV RNA load measurement taken early after human immunodeficiency virus (HIV) seroconversion was investigated in a cohort of 96 male patients with inherited bleeding disorders. Dates of HIV seroconversion had been estimated for all patients, and at least 4 HCV RNA load measurements per patient were done retrospectively after HIV seroconversion. HCV RNA load stabilized at 4 years after HIV seroconversion, and this point was used for analysis. There was a significant correlation between increased age and early HCV RNA load ( ; r p 0.25 P p ). Adjusting for HIV RNA levels, CD4 cell counts, and the age effect, HCV RNA load .01
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Prior to the introduction of heat sterilization in 1985, virtually all patients with hemophilia in the United Kingdom who were treated with large-pool clotting factor concentrates were infected with hepatitis C virus (HCV). Of these HCV-infected patients, 19 .5% [1] also became infected with human immunodeficiency virus (HIV). These patients were infected very early during the HIV epidemic, and many died before the introduction of highly active antiretroviral therapy (HAART) in 1996. Progression to AIDS dropped dramatically after this point, but the death rate remained high in these HIV and HCV coinfected individuals [2] .
The presence of HIV increases HCV RNA load and greatly accelerates liver disease progression [3, 4] , whereas the presence of HCV increases the risk of death or an AIDS-defining illness, as well as impairing CD4 ϩ T cell recovery during HAART [5] . The Royal Free Hospital Haemophilia cohort is one of the most extensively studied cohorts of male patients with hemophilia in the world [2, [6] [7] [8] . The impact of HIV coinfection on HCV disease progression can be seen in deaths from within this cohort, where 6 of 183 non-HIV-infected, HCV-positive patients died of liver-related disease, compared with 20 of 122 HIV coinfected individuals ( ) [2, 8] . Liver disease is P p .0002 patients were seen at the Centre at least every 3 months, at which time they underwent a clinical and laboratory review. Serum samples were taken regularly and stored for future use. The availability of these stored serum samples has enabled us to retrospectively test for HIV seropositivity and to estimate dates of HIV seroconversion for each patient [6] . Age at HIV seroconversion ranged from 1.9 to 77.8 years (median, 22.6 years), and all patients were infected with HCV either prior to or at the same time as they were infected with HIV. Patients were treated according to the guidelines in place at the time [22] . Since the end of 1995, patients with low CD4 cell counts have been offered HAART regimens including at least 1 nonnucleoside reverse-transcriptase inhibitor or protease inhibitor (PI). PIs are used with caution in this group, because of the possibility of liver complications in HCV-positive patients and spontaneous bleeding episodes in patients with hemophilia [23, 24] . Patients with CD4 cell counts of ! cells/L have been of-6 200 ϫ 10 fered prophylaxis against Pneumocystis carinii pneumonia (PCP) and Candida species infection since 1988, and patients whose CD4 cell counts fall to ! cells/L have been offered prophylaxis 6 50 ϫ 10 against Mycobacterium avium infection since 1991. However, because of immune reconstitution as a result of HAART, there is currently less need for prophylaxis, and this is now stopped once a patient's CD4 cell count increases to levels 1200 cells/mm 3 during HAART. Antiviral therapy for HCV was administered to 16 (14.4%) of the 111 patients in the cohort; 13 were treated with interferon monotherapy, and 3 were treated with interferon in combination with ribavirin. We have not controlled for the use of interferon in this study, because the doses used have been shown not to have an effect on HIV progression [8] . HAART was offered according to the guidelines in place at the time [22] , currently when CD4 cell counts fall to !300 cells/mm 3 . HCV genotyping and measurement of HIV-1 and HCV RNA loads. HCV RNA levels in the cohort have been measured retrospectively on serum samples annually from HIV seroconversion. Patients' serum samples had been stored at Ϫ40ЊC. HCV RNA levels were measured using an in-house quantitative-competitive reverse-transcriptase polymerase chain reaction (RT-PCR) assay (lower limit of detection, HIV RNA copies/mL; upper limit 4 1 ϫ 10 of detection, HIV RNA copies/mL) that has been de- 9 2.5 ϫ 10 scribed elsewhere [25] . Samples that tested negative in this assay were either treated as a categorical variable, where they were combined into a single group, or were replaced by the value of the limit of detection of the assay (10,000 copies/mL) for regression analysis. HIV RNA levels were measured using the Roche Amplicor HIV-1 Monitor version 1.0 assay plus add-in non-B primers (lower limit of detection, HIV RNA copies/mL; upper limit of detec-2 4 ϫ 10 tion, HIV RNA copies/mL; Roche Diagnostic Systems). 5 7.5 ϫ 10 These were measured prospectively since 1996 using the abovementioned assay, along with the ultrasensitive version of the assay (lower limit of detection, 50 HIV RNA copies/mL; upper limit of detection, 75000 HIV RNA copies/mL). In addition, HIV RNA loads have been measured retrospectively in this cohort as part of a previous study [26] . Samples that tested negative by either version of the assay were replaced by the value itself in the subsequent analyses (400 or 50 copies/mL, respectively). All HCV and HIV load measurements are reported as log values. No patients were excluded from analysis on the basis of persistent HCV RNA negativity. Where possible, patients from the cohort were genotyped for HCV using an RT-PCR, restriction fragment-length polymorphism-based assay, as described by Harris et al. [27] . Lymphocyte subset analysis has been routinely performed on all fresh samples at the hospital since 1982, as described elsewhere [25] .
An initial exploratory analysis of the data suggested that HCV RNA levels increased over the first 3-4 years of HIV infection, after which they appeared to stabilize. Three reasons could be given for the increase: inaccuracies in the estimated date of HIV seroconversion, the presence of HIV (resulting in increasing HCV RNA levels during that whole period of time), or HCV RNA degradation in the serum samples due to suboptimal handling and storage. To exclude the latter 2 reasons, we retested 10 HCV-positive samples that had been quantified in 1994 with the branched DNA (bDNA) assay (version 2.0; Bayer) using the same assay again. Samples had been stored at Ϫ20ЊC and freeze-thawed an unknown number of times. There was no significant difference between the 2 sets of values ( , sign rank test). In addition, it has been shown P p .82 that, after the initial increase in HCV virus load after HIV seroconversion, the yearly increase becomes nonsignificant [3, 28] , and this point was reached 4 years after HIV seroconversion.
Statistical methods. We considered the relationship between the first HCV RNA level measured at least 4 years after HIV seroconversion and progression to AIDS and all-cause mortality. AIDS was defined according to the Centers for Disease Control and Prevention definition in use in the United Kingdom at the time of diagnosis [29] . In Europe, only the clinical definition has been adopted, so this does not incorporate a CD4 cell count of !200 cells/mm 3 as an AIDS-defining characteristic. There were insufficient clinical end points for statistical analysis of deaths from liver disease. Of the total cohort of 111 patients with hemophilia, 15 (13.5%) had HCV RNA measurements taken only within the first 4 years after HIV seroconversion and could not be included in the analysis. Therefore, the total sample analyzed included 96 (86.5%) patients who had an HCV RNA level measured at least 4 years after HIV seroconversion. The 15 patients who were excluded from the analysis were older ( ), seroconverted to HIV in later P p .0006 calendar periods ( ), and, consequently, had shorter follow-P p .02 up ( ) than those who were included in the analysis. How-P p .03 ever, there were no differences in progression rates to AIDS, death, or hemophilia diagnosis.
After log transformation, the HCV RNA levels were approximately normally distributed. Therefore, HCV RNA levels were compared in those patients with different HCV genotypes by use of analysis of variance (ANOVA), and relationships between HCV RNA level and the patient's age at the time of HIV seroconversion and the CD4 cell count and HIV RNA level (after log transformation) at the time of the HCV RNA measurement were tested for significance using Pearson's correlation coefficient. CD4 cell counts and HIV RNA levels at the time of the HCV RNA measurement were defined as those values that had been measured closest in time to the HCV RNA level, always within a year of the HCV RNA measurement. A multivariate linear regression model was used to identify which of these factors were independently associated with the HCV RNA level.
To consider the relationship between the HCV RNA level and HIV disease progression, the patients were stratified into 3 groups on the basis of their HCV RNA level (groups were defined according to the tertiles of the observed distribution). Kaplan-Meier methods were used to illustrate progression to AIDS and death in the 3 groups, and the log-rank test was used to formally compare progression rates in the 3 groups. Patient follow-up was defined from the time of HIV seroconversion and was right-censored on 1 August 2000 if the patient remained alive and AIDS-free on this date. For progression to AIDS, patient follow-up was additionally right-censored if the patient died without receiving an AIDS diagnosis. Patient follow-up was also censored on the date of the last follow-up visit, when a patient was known to have transferred to another clinic. Cox proportional hazards regression models were used to quantify the relationships between HCV RNA level and progression to AIDS and death after adjusting for other important cofactors. For these analyses, although follow-up was defined from the date of seroconversion, follow-up was left-truncated to take account of late entry, because HCV RNA levels had been measured only у4 years after the date of HIV seroconversion. Because the Kaplan-Meier curves suggested that the relationship between the HCV RNA level and HIV disease progression was not linear, it was felt that it was unreasonable to include HCV RNA level as a continuous covariate in the Cox models. Therefore, the categorical grouping of HCV RNA was retained in this analysis. Other variables included in the model included the age of the patient at the time of seroconversion, HCV genotype (1a, 1b/1ab, 3, or other [genotype 2 or 4] ), CD4 cell count, and HIV RNA level at the time when the HCV RNA measurement was taken. The latter 2 variables were included in the Cox proportional hazards regression model as continuous variables after taking square root (CD4 cell count) and log 10 (HIV RNA) transformations. Because of the strong correlation between the use of antiretroviral therapy and the HIV RNA level and CD4 cell count and because patients who received treatment tended to be sicker than those who did not, the calendar year at the time of risk was used as a proxy for changing standards of care, including the availability of antiretroviral therapy. To do this, the calendar year was incorporated in the models as a time-updated covariate with binary variables, to indicate that the patient was being monitored during 3 periods (i.e., before 1992, 1992-1995, and 1997 or later, corresponding to the use of non/monotherapy, dual nucleoside reverse-transcriptase inhibitors, and HAART, respectively). An additional analysis was performed to identify whether the relationship between the baseline HCV RNA level and HIV disease progression could be explained by more-rapid increases in HIV RNA and decreases in CD4 cell count over the course of infection in those patients with higher HIV RNA levels. To perform this analysis, the CD4 cell count and HIV RNA level were included in the proportional hazards regression models as time-updated covariates that relate to HCV RNA and then indicate the independent effects of this measure on HIV progression, after adjusting for all the follow-up CD4 cell counts and HIV RNA levels. All analyses were performed using the SAS statistical software package [30] . 
Results
A description of the 96 patients included in the analysis and their laboratory measurements is shown in table 1. There was a positive correlation between the HCV RNA value and the patient's age at seroconversion ( ; ). There was r p 0.25 P p .01 also a significant difference between the HCV RNA levels in patients with different HCV genotypes ( , ANOVA; fig-P p .01 ure 1), with those patients with genotype 1a having the highest HCV RNA levels and those with genotype 2 or 4 (the "other" group) having the lowest values. There was no significant correlation, however, between HCV RNA level and either CD4 cell count ( ; ) or HIV RNA level ( ; r p Ϫ0.17 P p .11 r p 0.15 ) measured at the same time. Multivariate linear re-P p .16 gression analysis suggested that the effects of HCV genotype and age at HIV seroconversion were independent. Thus, the HCV RNA level was 0.03 log 10 copies/mL higher per additional year of age ( ) and, compared with patients with ge-P p .004 notype 1a, was 0.34 log 10 copies/mL lower ( ) in patients P p .32 with genotype 1b/1ab, 0.86 log 10 copies/mL lower in patients with genotype 3 ( ), and 1.01 log 10 copies/mL lower in P p .01 patients with other genotypes ( ; figure 1) . P p .005 By the end of August 2000, the cutoff date for the analysis, 52 (54.2%) of the 96 patients had developed AIDS, and 57 (59.4%) had died. The patients were stratified into 3 groups, according to the tertiles of the observed distribution of HCV RNA levels. Thus, 32 patients (33.3%) had HCV RNA levels !5.90 log 10 copies/mL ("low HCV RNA"), 33 patients (34.4%) had HCV RNA levels 5.90-6.86 log 10 copies/mL ("moderate HCV RNA"), and 31 patients (32.3%) had HCV RNA levels 16 .86 log 10 copies/mL ("high HCV RNA"). Kaplan-Meier analyses (figures 2 and 3) suggested that there was a relationship between the initial HCV RNA level and both end points. In particular, by 15 years after HIV seroconversion, 40.2%, 61.9%, and 55.3% of patients with low, moderate, and high HCV RNA levels, respectively, had progressed to AIDS ( , log-rank P p .13 test; figure 2), whereas 37.5%, 47.0%, and 61.3% had died by the same time point, respectively ( , log-rank test; figure 3 ). P p .08 Results from univariate Cox proportional hazards regression models (table 2) confirmed that there was an increased risk of AIDS and death in patients with HCV RNA levels 15.90 log 10 copies/mL. In addition, and as expected, patients with higher HIV RNA levels and lower CD4 cell counts at baseline also experienced faster progression to AIDS, as well as shorter survival. Contrary to expectations, there was no significant relationship between HCV genotype and progression to either end point in this group of patients, although those with HCV genotype 1a did experience more-rapid progression to each end point than did those with other genotypes. After adjusting for patient age, CD4 cell count, and HIV RNA level (all as fixed covariates) and calendar year (as a time-updated covariate), the effect of the initial HCV RNA level remained associated with both end points. Patients with HCV RNA levels 16.86 log 10 copies/mL had a 33% increase in the risk of developing AIDS ( ) and a 103% increase in the risk of death ( ). P p .50 P p .06 Patients with HCV RNA levels 5.90-6.86 log 10 copies/mL had a 139% increase in the risk of developing AIDS ( ) and P p .03 a 116% increase in the risk of death ( ). CD4 cell count P p .06 and HIV RNA level remained significantly associated with both end points in the multivariate analysis.
Finally, we were interested in whether the increased risk of AIDS and death in patients with higher HCV RNA levels could be explained by a more rapidly declining CD4 cell count or increasing HIV RNA levels. Thus, the analysis was repeated after adjusting for the changing CD4 cell count and HIV RNA levels as time-updated covariates. Table 3 illustrates the relative hazard (RH) for AIDS and death of the 3 HCV RNA levels, after adjusting for the changing CD4 cell count only, the changing HIV RNA level only, and both measurements as time-updated covariates. The results suggest that the greatest reduction in RH is seen after adjusting for the CD4 count; adjusting for the HIV RNA level after this had little additional effect on the RH. Thus, it is likely that patients with the highest HCV RNA levels tend to experience a more-rapid decline in their CD4 cell count over follow-up. 
Discussion
In this study, we investigated the prognostic value of HCV RNA levels measured retrospectively, after HIV seroconversion, in a cohort of 96 patients with hemophilia for whom dates of HIV seroconversion had been estimated previously [6] . The results show that a single HCV RNA load measurement taken ∼4 years after HIV seroconversion is predictive of clinical progression to AIDS and all-cause mortality over a period of at least 15 years. As has been reported elsewhere [15, 31] , there was a correlation between age at HIV seroconversion and HCV RNA load ( ; ); therefore, all our analyses have r p 0.25 P p .01 controlled for age. Using multivariate analysis, patients with HCV loads in the moderate virus load tertile (5.90-6.86 log 10 copies/mL) progressed significantly faster to AIDS than did those with virus loads in the low tertile (RH, 2.39; 95% confidence interval, 1.07-5.33;
). Surprisingly, there was no P p .03 significant relationship between the upper tertile of HCV load and progression to AIDS, and the reasons for this apparent discrepancy are unclear. However, the greatest reduction in RH for the high virus load category occurred when adjusting for changing CD4 cell counts rather than HIV RNA levels, whereas there were comparable reductions in RH for progression to AIDS in patients with moderate virus load levels (table 3) . These data imply that there may be substantial differences in the level of immunocompromise between these 2 groups that require further investigation.
We have also investigated whether a single HCV RNA load measurement taken early after HIV infection was predictive of death. In these analyses, similar RHs for the moderate and high HCV load tertiles were observed, which were of borderline significance ( , for both HCV load tertiles). Since these P p .06 analyses were performed after controlling for HIV load, the results are not just due to a correlation between HIV and HCV RNA loads. The data imply that sustained HCV replication early after HIV infection is a risk factor for death. Stratification of patients according to their HCV genotype showed that patients infected with genotype 1a also progressed more rapidly to death. This observation probably reflects the poor response of HCV genotype 1a to interferon therapy [32] but also confirms previous findings associating genotype 1a with accelerated disease progression in HIV coinfected patients [11] . Many studies have shown that coinfection with HIV increases the severity of HCV related liver disease, elevates HCV RNA load, and accelerates liver fibrosis [3, 33, 34] . In addition, coinfection with HCV in HIV-infected individuals has been associated with increased morbidity, mortality, and impairment of CD4 ϩ T cell recovery during HAART [5, 35] , although other studies have not observed such effects [36] [37] [38] [39] . Recent prospective longitudinal studies have also shown an association between HCV RNA load and progression to AIDS and response to HAART [5, 14] . Our results confirm and extend these studies, since the median followup in our study after HCV RNA load measurement was 15 years, whereas the former studies had substantially lower median follow-up periods from first HCV RNA load measurement (28 months and 7 years, respectively). In addition, associations between HCV RNA load and progression to AIDS and death did not appear until the ninth or twelfth year, respectively, after HIV seroconversion (figures 2 and 3). They would therefore have been missed in a study with shorter follow-up after initial HCV RNA load measurement.
It would have been interesting to examine the effect of the sequence of infection on HIV disease progression (i.e., first HCV then HIV coinfected, first HIV then HCV coinfected, or simultaneously coinfected). This analysis was not possible, because only 5 of the 71 patients (considering estimated exposure dates within 1 year of each other as simultaneous) were coinfected, and the rest were infected with HCV before HIV. Additionally, the long-term prognostic value of HCV RNA load should also be evaluated in cohorts of intravenous drug users, to take into account the effect of HIV and HCV reinfections after 1985.
In conclusion, our analyses show that HCV RNA levels measured early after HIV seroconversion are associated with an increased risk of AIDS and death, independently of other factors. However, further long-term follow-up of intensively studied cohorts and the inclusion of intravenous drug users are required to ascertain whether there is also an association between high levels of HCV load early in infection and liverrelated death. Nevertheless, early therapy for HCV infection may be warranted in HCV-HIV-coinfected individuals.
